Okey Stephanie 4

What Happened

• Stephanie Okey, a director of PTC Therapeutics (PTCT), sold 6,333 shares on March 5, 2026. The shares were sold at $63.38 each for a total proceeds of approximately $401,386. This was a sale (disposition), which is often routine and does not by itself indicate the insider's view on the company's prospects.

Key Details

• Transaction date and price: March 5, 2026 — 6,333 shares at $63.38 per share (total ≈ $401,386).
• Transaction type: Sale (S), described as open market or private sale in the filing.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The sale was effected pursuant to a written Rule 10b5-1 trading plan adopted by Ms. Okey on November 24, 2025 (Footnote F1).
• Filing timeliness: Form 4 was filed March 9, 2026; this appears to be within the standard two-business-day filing window for Form 4s.

Context

• Trades executed under a Rule 10b5-1 plan are prearranged and typically indicate the transaction followed a pre-set schedule or conditions rather than a contemporaneous decision based on new company information. Sales are common among insiders for diversification or liquidity needs; they are generally less informative than purchases about insider sentiment.